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SUMMARY Cyslosporin A (CyA) treatment of psoriasis is warranted 
in severe cases where other, conventional antipsoriatic approaches 
have failed. Gingival hyperplasia is a rare side effect of cyclosporin 
A treatment in psoriasis patients. Previous studies in cyclosporin A-
treated patients (mostly transplant recipients) have demonstrated 
correlation between cyclosporin A serum levels and oral hygiene 
status on the one hand, and the prevalence and severity of this 
overgrowth on the other hand. Severe cases of gingival overgrowth 
may call for radical treatments such as periodontal surgery. Our 
aim was to present a severe form of cyclosporin A-induced 
hyperplasia in two female patients and to give an overview of the 
current literature on the issue. High serum levels of cyclosporin 
A were observed in both patients. Moreover, high initial plaque 
accumulation was noted in both patients. Upon cessation of drug 
administration and a combined periodontal treatment, virtually 
complete reduction of the gingival enlargement and inﬂammation 
was observed. Consequently, early diagnosis and an all-inclusive 
treatment of cyclosporin A-induced hyperplasia can result in 
virtually complete remission of the symptoms and eliminate the 
need of aggressive treatments such as periodontal surgery.




 Cyclosporin A (CyA) is a hydrophobic, cyclic 
polypeptide derived from the fungus Tolypocla-
dium inﬂatum Gams. Early investigations showed 
the drug to have a potent inhibitory effect on lym-
phocyte proliferation (1-3), speciﬁcally acting on 
the T cell response, with little, if any, action on the 
B cells (3-6), without being cytotoxic or myelosup-
pressive at the same time (7). For that reason, 
CyA is a key drug used for immunosuppression 
necessary for the prevention of transplant rejec-
tion. Moreover, CyA has also tremendous thera-
peutic value in the treatment of disorders where 
aberrant immunoregulation is considered to be an 
etiologic factor, such as type I (insulin dependent) 
diabetes, systemic lupus erythematosus, polymy-
ositis, acute dermatomyositis, Crohn’s disease, 
ocular Behçet’s syndrome, endogenous uveitis, 
psoriasis, atopic dermatitis, rheumatoid arthritis, 
and pemphigus vulgaris (3,8), just to name a few.
 CyA is a potent immunosuppressor because it 
interferes with the activation of the cytotoxic and 
helper T cells, thereby impeding the immune re-
sponse. Cytokines, soluble factors secreted by 
lymphocytes and monocytes, regulate the immune 
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response to infection, cancer, and transplanted or-
gans. CyA blocks transcription of genes involved 
in T lymphocyte activation by inhibiting calcineu-
rin phosphatase, an intracellular signaling path-
way that regulates the expression of cytokines. 
Speciﬁcally, activated calcineurin is responsible 
for nuclear translocation of the transcription fac-
tor-cytoplasmic nuclear factor of activated T cells 
(NFAT). The orchestrated activation of NFAT and 
other transcription factors allows for the expres-
sion of cytokines such as interleukin (IL)-4, IL-2, 
and interferon (IFN)-γ, among others (9-14). Since 
IL-4, IL-2, and IFN-γ are important for the activa-
tion of both type 2 and type 1 helper T cells, re-
spectively, CyA shuts down the cellular branch of 
the immune system. Thus, CyA prevents the gen-
eration of mature T helper cells (13-16), without an 
inhibitory effect on previously activated cytotoxic 
cells (17) or T-suppressor cells.
 CyA is usually administered orally. The oral 
therapeutic dose for immunosuppression is 10 to 
20 mg/kg body weight/day, which results in a se-
rum concentration of 100 to 400 ng/ml (18), and 
plasma half life of 17 to 40 hours (19,20). Exten-
sive metabolism of CyA in the liver results in at 
least 12 metabolites, which have minimal immu-
nosuppressive properties (21,22).
 The most common adverse effect of CyA is a 
decreased glomerular ﬁltration rate (23-25), which 
is initially largely asymptomatic. The most visible 
side effect of CyA therapy is gingival hyperplasia 
(GH). It is of no surprise, therefore, that it was 
among the ﬁrst reported side effects of CyA (26-
28). In most cases, gingival overgrowth occurs 
within 3 months of CyA treatment. The prevalence 
of CyA-induced gingival overgrowth is extremely 
variable (27%-81%) (29,30), which is most likely 
due to drug dosage, duration of therapy, method 
of assessment of gingival overgrowth, and the 
medical condition for which the drug was being 
used.
 CyA-induced gingival overgrowth starts as a 
papillary enlargement which is more pronounced 
on the labial aspects of the gingival mucosa and 
in-between the teeth (interdental papillae area) 
than on the palatal or lingual surfaces. Over time, 
the papillary enlargements increase in size and 
coalesce with each other, making the gingivae 
hard, swollen, rounded and lobulated. Overgrowth 
is largely limited to the width of the gingivae, al-
though it can extend coronally and interfere with 
the occlusion, mastication and speech. The hyper-
plastic gingival tissues are often highly inﬂamed, 
bleeding readily on probing.
 
 The relation between CyA dosage and de-
gree of gingival hypertrophy has been subject to 
debate. Some studies have shown that gingival 
overgrowth is related to high doses of CyA in the 
plasma or saliva, or later stages of the CyA regi-
men (31-36). The presence of dental plaque in-
creases the likelihood of gingival hyperplasia in 
CyA-treated patients, as it may provide a reservoir 
for the accumulation of CyA (33,36-38). No asso-
ciation between sex or age has been shown for 
development of gingival hyperplasia in response 
to CyA therapy (36,38,39). It has been postulated 
that HLA-DR1 is protective, while other HLA types 
correlate with increased susceptibility to gingival 
hyperplasia in response to CyA (39-42). Interest-
ingly, however, high degree of HLA-A mismatching 
between the host and donor might be protective 
for GH development in renal transplant recipients 
on CyA therapy (38).
 Histologically, it is not known for sure if CyA-
induced gingival hyperplasia is a true hyperplasia 
because enlargement may not result simply from 
an increase in the number of cells but from the 
increase in extracellular tissue volume. The over-
lying epithelium is of variable thickness, irregular, 
and multilayered, with acanthosis, parakeratosis 
and pseudoepitheliomatous proliferation. The epi-
thelial ridges penetrate deep into the subepithelial 
connective tissue. Microscopic examination shows 
sparsely vascular ﬁbrous connective tissue with 
thick, dense, interlacing bundles of collagen ﬁbers 
with an inﬂammatory inﬁltrate, primarily plasma 
cells. CyA is known to increase the level of col-
lagen in the gingival tissue by inducing collagen 
production (43,44), and by inhibiting the degrada-
tion of collagen by gingival ﬁbroblasts (45,46). Af-
ter all, IL-1 has been known for long time to induce 
the production of collagenase (47), which normally 
degrades collagen, and CyA indirectly reduces 
the levels of IL-1 secreted by monocytes, which, 
in turn, could explain the accumulation of colla-
gen in the gingivae in patients taking CyA. CyA 
also lowers free cytosolic calcium levels (48,49), 
which, in turn, can impair extracellular collagen 
degradation and increase noncollagenous secre-
tions by ﬁbroblasts (50). However, in addition to 
the increase of collagen synthesis, there are re-
ports on a decrease in protein/collagen synthesis 
(51,52) as well as on a failure to alter protein syn-
thesis (53,54). Another complicating factor is that 
CyA has also been observed to increase the levels 
of noncollagenous matrix (55).
 CyA is also known to have ﬁbroblast prolifera-
tion properties, and there have been indications 
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that changes in ﬁbroblast cell density occur as the 
lesion progresses (50,56). However, some reports 
claim that there are no changes of the cell prolifer-
ation rates in hyperplastic lesions (51,52). These 
seemingly contradictory ﬁndings could potentially 
be due to the ﬁbroblast heterogeneity in each of 
these studies. After all, the actual scenario may in 
fact be an all-inclusive one that takes into account 
many of the different results.
 Treatment of gingival overgrowth in CyA-treat-
ed patients has usually focused on maintenance 
of strict oral hygiene together with scaling and root 
planing, or attempting to replace CyA with another 
drug whenever possible. If these two approaches 
fail, a more aggressive treatment is warranted, 
such as periodontal surgery.
 So far, CyA-induced gingival outgrowth has 
been mainly described in organ transplanted pa-
tients. However, CyA is also effective in the treat-
ment of severe psoriasis (57-60). Psoriasis is 
a chronic autoimmune skin disease induced by 
autoreactive IFN-γ producing T helper cell (Th) 1 
lymphocytes which orchestrate other cellular re-
actions, resulting in hyperproliferation of kerati-
nocytes (acanthosis), concomitant inﬂammation, 
and dermal proliferation of small vessels (61-63). 
Given that CyA inhibits T cell function, it is a logi-
cal choice from an efﬁcacy standpoint in the treat-
ment of psoriasis. After all, rapid improvements 
in the prognosis have been observed in psoriasis 
patients treated with CyA at 2.5-5.0 mg/kg/day. In 
what seems to be the most comprehensive study 
on the side effects of CyA treatment in psoriasis 
patients, gingival enlargements were observed in 
only 19 (mere 4.3%) out of 422 patients participat-
ing in the study (64), which is well in accordance 
with other reported studies (60,65), but still signiﬁ-
cantly lower than that observed in CyA treatment 
of transplant recipients (29,30). As such, gingival 
enlargement is a rare side effect of CyA therapy 
during the treatment of psoriasis.
 Two cases are presented of severe and rare 
CyA-induced gingival outgrowth in two female pa-
tients who were treated for an aggressive form of 
psoriasis.
CASE REPORTS
Two female patients aged 45 and 52, suffering from 
severe and resistant forms of psoriasis (erythro-
dermica/arthropathica), presented to Department 
of Dermatology, Skopje University Hospital Cen-
ter in Skopje, Republic of Macedonia. Many treat-
ment modalities (topical steroids, calcipotriol, pho-
totherapy with UVB, photochemotherapy (PUVA) 
and PUVA-retinoids (re-PUVA)) were tried in the 
patients. Since they did not respond sufﬁciently 
to these conventional therapeutic measures, and 
moreover, phototherapy and chronic exposure to 
photochemotherapy implies an increased risk of 
photocarcinogenicity, a systemic approach with 
CyA was undertaken. The patients had no per-
sonal or family history of any conditions that may 
be exacerbated by CyA, including but not limited 
to hypertension, renal disease, cancer, migraine, 
and vascular disease (66,67). They were initially 
treated with CyA at a mean dosage of 2.7 mg/kg/
day for 6 weeks, with some favorable response. 
Plasma CyA levels reached 310 and 290 ng/ml for 
the two patients in that period. On oral examina-
tion, the gingivae were signiﬁcantly enlarged by 
the end of the ﬁrst 6 weeks of CyA treatment, but 
did not interfere with any normal function. CyA 
therapy was continued for a total of 6 months with 
gradual dose reduction until complete discontinu-
ation of the medication. During the following pe-
riod, gradual worsening of the gingival condition 
was observed. Speciﬁcally, the gingivae were so 
enlarged that most of the patients’ teeth were cov-
ered by tissue overgrowth (Fig. 1). The most affect-
ed regions were the interproximal papillae in the 
anterior segments of the jaw, incisors and canine 
teeth, particularly their labial (vestibular) surfaces. 
Moreover, the gingival enlargement was accom-
panied by severe inﬂammation, constant pain and 
spontaneous gingival bleeding. An abundance of 
plaque was found surrounding the enlarged tissue. 
 The patients received detailed oral hygiene 
instructions at the beginning of treatment; how-
ever, they complied poorly with these instructions. 
Upon worsening of the gingival enlargements, the 
Figure 1. Marked gingival hyperplasia due to 
cyclosporin A.
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patients were instructed to undergo professional 
periodontal treatment. Scaling and root planing 
under local anesthesia were performed in order to 
signiﬁcantly improve their oral hygiene. Within a 
month of periodontal treatment, visible reduction 
in the gingival overgrowth and inﬂammation was 
achieved.
 No other adverse events in response to CyA 
therapy were reported. No renal dysfunction, hy-
pertension, infections or malignancies were ob-
served in these patients while on CyA treatment 
or during the 6-month follow-up. No abnormalities 
in the electrolyte panel, renal state (calcium, phos-
phate, magnesium, blood urea nitrogen, and two 
baseline measurements of serum creatinine), uric 
acid, liver function tests, cholesterol, triglycerides 
and complete blood count were recorded.
 Erythrodermic and arthropathic psoriasis re-
sponded only moderately to this CyA regimen. At 
the end of CyA therapy, remission of the gingival 
changes to normal was achieved. Similarly, during 
the 6-month follow-up, the gingival enlargements 
disappeared completely, with little residual gingi-
val inﬂammation.
DISCUSSION
 Psoriasis is a complex disease. First, the sim-
ple manifestation of psoriasis requires genetic 
predisposition towards abnormal keratinocyte 
proliferation and differentiation. In addition, the 
appearance of psoriasis needs an initiating event 
that involves a potent proinﬂammatory cocktail of 
cytokines resulting in hyperproliferation of kerati-
nocytes, concomitant inﬂammation, and dermal 
proliferation of small vessels (61-63). Therefore, 
blocking the aberrant inﬂammatory environment in 
the affected areas improves prognosis. CyA is a 
potent inhibitor of the immune response (13-16), 
and as such a good candidate for the manage-
ment of psoriasis in cases where other treatments 
have failed. However, CyA is associated with a 
signiﬁcant incidence of side effects, such as gin-
gival hyperplasia. The severity of this side effect 
has been correlated with high serum and/or saliva 
levels of CyA (31-36), and the presence of dental 
plaque (33,36-38). Our patients had serum levels 
of 310 and 290 ng/ml, which were at the high end 
of normally observed CyA serum levels of 100 to 
400 ng/ml (18). More important, our patients had 
a signiﬁcant plaque accumulation at the beginning 
of treatment. The management of plaque accumu-
lation proved to be crucial in reducing the CyA-
induced enlargements since the ﬁrst reductions in 
the overgrowths were observed after the recom-
mended periodontal treatments during CyA ther-
apy. The end of CyA treatment marked an even 
more rapid reduction of the gingival inﬂammation 
and enlargements.
 To sum up, two uncommonly severe cases of 
CyA-induced hyperplasia in two psoriasis patients 
are presented, accompanied by a discussion on 
the etiology of this rare scenario. In addition, this 
report introduces an effective therapy involving re-
duction of dental plaque levels in both patients in 
a timely manner as a way to reduce gingival en-
largements in CyA-treated psoriasis patients with 
almost no longterm side effects, thereby eliminat-
ing the need of more invasive approaches, such 
as periodontal surgery/gingivectomy. 
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